The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Exciting combinations under investigation in lymphoma
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MI, talks on novel combinations on the horizon for the treatment of lymphoma, highlighting studies assessing the addition of ruxolitinib or vorinostat to PD-1 blockade in Hodgkin lymphoma and polatuzumab vedotin plus chemotherapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
